Eagle Pharmaceuticals Inc buy klostergang
Start price
23.06.15
/
50%
€77.64
Target price
23.12.15
€95.00
Performance (%)
9.73%
End price
23.12.15
€85.20
Summary
This prediction ended on 23.12.15 with a price of €85.20. With a performance of 9.73%, the BUY prediction by klostergang for Eagle Pharmaceuticals Inc closed with a slight gain. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -0.383% | 1.093% | 11.642% | 60.422% |
| iShares Nasdaq 100 | -0.411% | -1.973% | 7.273% | 87.823% |
| iShares Nikkei 225® | 1.838% | 10.261% | 31.381% | 66.929% |
| iShares S&P 500 | -0.712% | 0.445% | 4.295% | 60.457% |
Comments by klostergang for this prediction
In the thread Eagle Pharmaceuticals Inc diskutieren
Fly like :
- Eagle Pharmaceuticals (NASDAQ:EGRX) submits a New Drug Application (NDA) to the FDA for a stable liquid intravenous formulation (ready-to-use or RTU) of bivalirudin for the treatment of patients undergoing percutaneous coronary intervention (PCI) in the following scenarios: with the use of a glycoprotein IIb/IIIa inhibitor or at risk of heparin-induced thrombocytopenia and thrombosis syndrome and patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.
- RTU bivalirudin, intended for use with aspirin, contains the same active ingredient as The Medicines Company's (NASDAQ:MDCO) Angiomax (bivalirudin), but eliminates the need for reconstitution/dilution.
- Angiomax generated ~$600M in sales in 2014.
- Bivalirudin is an anticoagulant that inhibits thrombin.
(Laufzeit überschritten)